Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
Product: | Noralin |
Active Ingredient: | Noradrenaline acid tartrate monohydrate 0.12mg/mL equivalent to noradrenaline 0.06mg/mL |
Dosage Form: | Solution for infusion |
New Zealand Sponsor: | Boucher & Muir (New Zealand) Limited t/a BNM Group |
Manufacturer: | Sintetica-Bioren SA, Couvet, Switzerland |
Product: | Noralin |
Active Ingredient: | Noradrenaline acid tartrate monohydrate 0.2mg/mL equivalent to noradrenaline 0.1mg/mL |
Dosage Form: | Solution for infusion |
New Zealand Sponsor: | Boucher & Muir (New Zealand) Limited t/a BNM Group |
Manufacturer: | Sintetica-Bioren SA, Couvet, Switzerland |
Product: | Noralin |
Active Ingredient: | Noradrenaline acid tartrate monohydrate 0.24mg/mL equivalent to noradrenaline 0.12mg/mL |
Dosage Form: | Solution for infusion |
New Zealand Sponsor: | Boucher & Muir (New Zealand) Limited t/a BNM Group |
Manufacturer: | Sintetica-Bioren SA, Couvet, Switzerland |
Product: | Noralin |
Active Ingredient: | Noradrenaline acid tartrate monohydrate 0.4mg/mL equivalent to noradrenaline 0.2mg/mL |
Dosage Form: | Solution for infusion |
New Zealand Sponsor: | Boucher & Muir (New Zealand) Limited t/a BNM Group |
Manufacturer: | Sintetica-Bioren SA, Couvet, Switzerland |
Dated this 5th day of August 2020.
CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).